Annexon, Inc. Stock Price, News & Analysis

Annexon, Inc. (Nasdaq: ANNX) announced on February 16, 2023, the granting of equity inducement awards to four new non-executive employees. This initiative aligns with the 2022 Employment Inducement Award Plan and complies with Nasdaq Listing Rule 5635(c)(4). A total of 182,000 stock options were issued, each priced at $5.90, the closing price on the grant date. These options have a ten-year term and vest over four years, with 25% vesting on the first anniversary of employment. Annexon focuses on developing innovative complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders, with multiple clinical trials expected in 2023.

Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company, has granted a significant equity inducement award to its chief scientific officer, Dean “Rick” Artis, Ph.D. The award, effective January 15, 2023, includes an option to purchase 210,000 shares at an exercise price of $6.84, the closing price on January 13, 2023. This option has a ten-year term and will vest over four years. Annexon is focused on developing complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders, with multiple clinical trials underway and anticipated readouts throughout 2023 and beyond.

Annexon, Inc. (Nasdaq: ANNX) announced significant advancements in its clinical trials for novel complement therapies. The company aims to achieve critical milestones in 2023, including the expanded enrollment of its Phase 3 trial for ANX005 in Guillain-Barré syndrome and the initiation of a pivotal trial for Huntington’s disease. Annexon plans to present updates at the J.P. Morgan Healthcare Conference on January 11, 2023. With $269.5 million in cash, the company has a robust operating runway extending into 2025, positioning itself strongly for continued development in the autoimmune and neurodegenerative disease sectors.

Annexon, Inc. (Nasdaq: ANNX) announced the appointment of Dr. Dean “Rick” Artis as chief scientific officer, succeeding Dr. Larry C. Mattheakis. Dr. Artis returns after serving as CSO at Octant Bio, having previously led key developments at Annexon. He will oversee all research efforts, focusing on enhancing the company's pipeline of classical complement inhibitors for autoimmune and neurodegenerative diseases. Annexon's pipeline is expected to yield significant clinical data throughout 2023, indicating a potential transformational period for the company.

Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company, announced that its CEO, Douglas Love, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 7:30 a.m. PT in San Francisco. The presentation will be available via live webcast on the Annexon website, and a replay will be accessible for 30 days after the event.

Annexon focuses on developing novel complement medicines targeting autoimmune, neurodegenerative, and ophthalmic disorders, with several clinical trials expected to yield results throughout 2023.

Annexon, Inc. (Nasdaq: ANNX) announced the grant of an equity inducement award to a new non-executive employee on November 16, 2022, under its 2022 Employment Inducement Award Plan. The award consists of an option to purchase 5,000 shares at an exercise price of $5.77 per share. The option vests over four years, with 25% vesting after the first year and monthly thereafter. Annexon focuses on developing complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders, with clinical readouts expected throughout 2023 and beyond.

Annexon, a clinical-stage biopharma, reported Q3 2022 results with a net loss of $35.1 million ($0.51 per share), an improvement from $35.6 million ($0.93 per share) a year earlier. Cash reserves are $269.5 million, sufficient to fund operations into H2 2025. The company is advancing trials for its complement-targeted therapies, including late-stage studies for ANX005 in Guillain-Barré Syndrome and Huntington’s disease. Upcoming presentations at scientific conferences will showcase its novel approaches and preclinical progress on ANX007 for geographic atrophy.

Annexon, Inc. (Nasdaq: ANNX) announced the granting of equity inducement awards to three new non-executive employees under its 2022 Employment Inducement Award Plan. The awards, approved on October 17, 2022, involve options to purchase 87,400 shares of common stock, with an exercise price of $5.63 per share, reflecting the closing stock price on the grant date. The options have a ten-year term and vest over four years. Annexon focuses on developing complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders.

Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company, announced the granting of equity inducement awards to three new non-executive employees under its 2022 Employment Inducement Award Plan. This decision, made on September 15, 2022, complies with Nasdaq Listing Rule 5635(c)(4). The new employees received options to purchase a total of 125,000 shares of common stock, at an exercise price of $6.34 per share. The options have a ten-year term and will vest over four years, with the first 25% vesting on the first anniversary of their employment.